Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

Abstract:
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

Houston, TX | Posted on November 14th, 2011

Leonardo was founded based on the breakthrough multi-stage drug delivery technology of Dr. Mauro Ferrari, President of the Methodist Hospital Research Institute in Houston. The Company's primary technology is based on micron-sized particles of porous silicon that are loaded with a variety of secondary nanoparticles containing a therapeutic agent, such as a drug or small interfering RNA molecule. These silicon particles protect their payload from several key defenses used by the body and many cancers to thwart the effective delivery of therapeutic agents. Fundamental proof of concept was demonstrated last year in a collaborative effort with the University of Texas Health Science Center in Houston and the MD Anderson Medical Center (Cancer Research, 2010. 70(9): p. 3687-3696), with further proof of concept work ongoing.



The Company achieved a major breakthrough with the initial TETF investment by demonstrating a manufacturing process that it believes can be scaled-up economically to produce sufficient particles for human dosing and eventual commercialization. The second tranche of TETF funds will now be used to design, test and validate the commercial manufacturing process and to initiate toxicology testing as a necessary intermediate step on the way to human trials.



"We are excited to receive this second investment from the TETF," said Bruce D. Given, M.D., Chief Executive Officer of Leonardo Biosystems. "Having demonstrated the feasibility of a high volume manufacturing process necessary for commercialization, we are looking forward to moving ahead aggressively with our development program."



About Leonardo's multi-stage system

Leonardo's lead technology consists of fully biodegradable, porous silicon particles smaller than a red blood cell, which can be loaded with a diverse array of secondary nanoparticles such as liposomes, micelles, carbon nanotubes, dendrimers and metallic nanoparticles. In addition to bypassing many of the body's natural defenses that lead to rapid clearance of nanoparticles administered alone, Leonardo's particles can be designed to seek out tumor vasculature and can be tuned to create an intravascular depot, providing sustained release following a single intravenous injection.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead is a leader in delivering small RNAs for gene silencing, and has programs in anti-obesity therapeutics and regenerative medicine.

About Leonardo Biosystems, Inc.

Leonardo Biosystems is a drug delivery company built around technology developed by Dr. Mauro Ferrari, one of the world's best-known nano-science innovators. Leonardo has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. Leonardo is a portfolio company of Arrowhead Research Corporation (NASDAQ: ARWR).

For more information, please click here

Contacts:
Investor Relations Contact:

Brandi Floberg
or Kathy Price
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Premier Healthcare Pitch Competition comes to Atlanta this May April 12th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014

Nanomedicine

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014

Announcements

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE